Clinical trials: Metabolic Control, active
Type 1 Diabetes, Children
Think-Find-Solve Activities for Insulin Self-Management in Type 1 Diabetes
Children with type 1 diabetes require lifelong insulin therapy. However, improper management of insulin therapy may lead to serious, potentially life-threatening complications.
- Conditions
- Type 1 Diabetes, Children, Activity, Insulin
- Trial name
- NCT07670572
- Testing
- Insulin Self-Management Know-Find-Solve Activity Book, Routine education
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Marmara University
Overweight , Obesity
Efficacy and Safety of Akkermansia Muciniphila AKM Lab-01 for Overweight and Obesity
This study is designed as a preliminary investigation to evaluate the weight-loss efficacy and safety of AKM Lab-01 in an overweight or obese population.
- Trial name
- NCT07331974
- Testing
- AKM Lab-01
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Moon (Guangzhou) Biotechnology Co., Ltd.
Type 1 Diabetes, Closed Loop
Semi-closed Loop Automated Insulin Therapy in the Pediatric Population Aged 2-6 Years With Type 1 Diabetes: Impact on Quality of Life and Glycemic Control
The incidence of type 1 diabetes is increasing, with an incidence of +4% per year in France today. The treatment for type 1 diabetes is insulin therapy.
- Conditions
- Type 1 Diabetes, Closed Loop, Insulin, Quality of Life
- Trial name
- Diablife (NCT06875167)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Fondation Lenval
Gastric Cancer (GC), Iron Deficiency Anemia (IDA)
Ferric Carboxymaltose Versus Iron Sucrose for Iron Deficiency Anemia After Radical Gastrectomy for Gastric Cancer
This is a multicenter, open-label, randomized controlled trial. A total of 160 patients with iron-deficiency anemia after radical gastrectomy for gastric cancer will be enrolled and randomly assigned in a 1:1 ratio.
- Conditions
- Gastric Cancer (GC), Iron Deficiency Anemia (IDA), Post-Operative Anemia, Radical Gastrectomy
- Trial name
- IRIS (NCT07772453)
- Testing
- Ferric Carboxymaltose (FCM), Iron Sucrose.
- Volunteers
- 160 people
- Sponsor
- Zhaojian Niu,MD
Pulpitis - Irreversible, Vitamin D Deficiency
Effect of Vitamin D on Postoperative Pain in Symptomatic Irreversible Pulpitis
Vitamin D deficiency (VDD) is a prevalent global health concern that has been linked to altered pain perception through its effects on inflammatory pathways, nociceptor activity, and neurotrophic signaling.
- Trial name
- NCT07579637
- Testing
- Vitamin D3
- Where
- Egypt
- Volunteers
- 54 people
- Sponsor
- Future University in Egypt
Glycogen Storage Disease Type I
Dietary Treatment Strategies and Metabolic Control in Glycogen Storage Disease Type I
The present project will specifically assess metabolic effects of dietary interventions with controlled intake of fructose and fructose/galactose in GSDI, with the aim to provide evidence whether relaxed dietary restrictions of…
- Trial name
- GSD-DIET (NCT06852612)
- Testing
- Fructose, Fructose and galactose
- Where
- 2 sites in Switzerland
- Volunteers
- 20 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Obesity and Overweight
The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity（SPARKLE）
This is a multicenter, double-blind, randomized, placebo-controlled phase Ⅱ study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of YN-011 in subjects with overweight (27 kg/m2 ≤ BMI < 30 kg/m2, with at…
- Trial name
- NCT07114419
- Testing
- Efsubaglutide Alfa 20 mg QW, Efsubaglutide Alfa 40 mg QW, Efsubaglutide Alfa 40 mg Q2W
- Where
- 5 sites in Australia
- Volunteers
- 200 people
- Sponsor
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Acute Coronary Syndromes (ACS), Hypercholesterolemia
Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome
The goal of this clinical trial is to evaluate whether triple lipid-lowering therapy (atorvastatin, ezetimibe, and bempedoic acid) is more effective than dual therapy (atorvastatin and ezetimibe) in reducing LDL cholesterol…
- Trial name
- TLD-ACS (NCT07508254)
- Testing
- Atorvastatin 40 Mg Oral Tablet, Ezetimibe 10 mg, Bempedoic Acid 180 MG Oral Tablet
- Where
- Pakistan
- Volunteers
- 120 people
- Sponsor
- Punjab Institute of Cardology
Cystic Fibrosis, Pancreatic Insufficiency
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
In recent years, diabetes has emerged as one of the most significant co-diseases that many Cystic Fibrosis (CF) patients develop.
- Trial name
- NCT01851694
- Testing
- GLP-1, GIP
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Diabetes
EFFECTIVENESS OF A TRIPLE NUTRITIONAL INTERVENTION AND PHYSICAL IN PREDIABETIC PATIENRS
Diabetes represents a substantial burden on health care systems. People with prediabetes IGT (impaired glucose tolerance) or IFG (impaired fasting glucose) are at high risk of developing diabetes, and up to 50% progress to…
- Trial name
- NCT06820775
- Testing
- A TRIPLE INTERVENTION NUTRITION AND PHYSICAL ACTIVITY
- Where
- Spain
- Volunteers
- 82 people
- Sponsor
- Bioaraba Health Research Institute
Type 1 Diabetes
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).
- Trial name
- SAFEGUARD (NCT07187531)
- Testing
- High Dose SAB-142, Low Dose SAB-142
- Where
- 68 sites in United States, Australia and 13 more
- Volunteers
- 159 people
- Sponsor
- SAb Biotherapeutics, Inc.
Obesity
Probiotic for Weight Management in Overweight and Obese Adults
To evaluate the impact of pasteurized Akkermansia muciniphila Akk11 capsules versus placebo on body composition (including body weight, BMI, body fat percentage, waist-to-hip ratio, wrist circumference, visceral fat area, and…
- Trial name
- NCT07507929
- Testing
- Probiotic
- Where
- China
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Phenylketonuria
A Study of JNT-517 in Participants With Phenylketonuria (PKU)
This Phase 3 study will evaluate the safety, effectiveness, tolerability, and how the body processes JNT-517 in children, adolescents, and adults with phenylketonuria.
- Trial name
- NCT06971731
- Testing
- JNT-517
- Where
- 26 sites in United States, Australia and 8 more
- Volunteers
- 120 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
- Trial name
- BARICADE-DELAY (NCT07222137)
- Testing
- Baricitinib
- Where
- 112 sites in United States, Australia and 17 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Latent Autoimmune Diabetes in Adults (LADA)
Hybrid Closed-Loop System in LADA Patients: A Randomized Trial
Based on the difficulties in blood glucose control among the Latent Autoimmune Diabetes in Adults (LADA) population and the deficiencies of previous studies, this research aims to conduct a clinical comparative study.
- Trial name
- NCT06941675
- Testing
- Hybrid Closed-Loop Artificial Pancreas System
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanxi Bethune Hospital
Type 2 Diabetes (T2DM), Obesity Type 2 Diabetes Mellitus
DIabetes GLycemic Assessment in Newly Confirmed Episodes
This is a prospective, open-label, randomized controlled trial involving 80 adult patients with newly diagnosed T2DM (diagnosed within the last 3 months) recruited at the Bogomolets National Medical University.
- Conditions
- Type 2 Diabetes (T2DM), Obesity Type 2 Diabetes Mellitus, Obesity & Overweight, Insulin Resistance
- Trial name
- DI-GLANCE (NCT07690163)
- Testing
- CGM Sibionics, On-Call Extra Glucometer
- Where
- 3 sites in Ukraine
- Volunteers
- 80 people
- Sponsor
- Nazarii Kobyliak
Kidney Diseases, Dialysis; Complications
PRevEnting FracturEs in REnal Disease - 1
PREFERRED-1 is a pilot study designed to determine the feasibility of a large randomized, pragmatic, open-label, comparative-effectiveness trial of denosumab for the prevention of fragility fractures in people receiving…
- Conditions
- Kidney Diseases, Dialysis; Complications, Fragility Fracture, Chronic Kidney Disease-Mineral and Bone Disorder
- Trial name
- PREFERRED-1 (NCT05096195)
- Testing
- Denosumab 60 mg/ml, Calcium and vitamin D prophylaxis, Monitoring of post-injection calcium and phosphate
- Where
- 6 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Western University, Canada
Type 2 Diabetes Mellitus (T2DM), Malnutrition
Nutritional Management of the Patient With Type 2 Diabetes at Nutritional Risk or With Malnutrition in Clinical Practice
The objective of this observational study is to characterize the patient profile and nutritional treatment patterns of individuals with type 2 diabetes (T2D) or drug-induced diabetes who present with malnutrition, or are at risk…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Malnutrition, Malnourishment, Drug-Induced Diabetes
- Trial name
- STARLIGHT (NCT07252765)
- Where
- 12 sites in Spain
- Volunteers
- 334 people
- Sponsor
- Outcomes'10
Bladder, Lower Urinary Track Symptoms
Low-Energy Shock Wave Therapy for Overactive Bladder in Women With Metabolic Syndrome
Overactive bladder (OAB) is a common condition that causes urinary urgency, frequent urination, and nocturia, which can significantly affect quality of life.
- Conditions
- Bladder, Lower Urinary Track Symptoms, Metabolic Syndrome, Urgency-Frequency
- Trial name
- NCT07563764
- Testing
- Low-Energy Extracorporeal Shock Wave Therapy (LiESWT)
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- KMUHIRB-F(I)-20230051
Alzheimer's Disease
A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects
This study is a Phase 2b/3 clinical trial of a new candidate drug (T3D-959) to treat patients with mild-to-moderate Alzheimer's.
- Trial name
- NCT06964230
- Testing
- T3D-959
- Where
- United States
- Volunteers
- 376 people
- Sponsor
- T3D Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.